These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 25416282)
21. VPS35-deficiency results in an impaired AMPA receptor trafficking and decreased dendritic spine maturation. Tian Y; Tang FL; Sun X; Wen L; Mei L; Tang BS; Xiong WC Mol Brain; 2015 Oct; 8(1):70. PubMed ID: 26521016 [TBL] [Abstract][Full Text] [Related]
22. Contributions of VPS35 Mutations to Parkinson's Disease. Rahman AA; Morrison BE Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Sargent D; Moore DJ Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708 [TBL] [Abstract][Full Text] [Related]
24. Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway. Huang Y; Huang H; Zhou L; Li J; Chen X; Thomas J; He X; Guo W; Zeng Y; Low BC; Liang F; Zeng J; Ross CA; Tan EK; Smith W; Pei Z Hum Mol Genet; 2022 Nov; 31(22):3886-3896. PubMed ID: 35766879 [TBL] [Abstract][Full Text] [Related]
25. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex. Macías-Calvio V; Fuentealba LM; Marzolo MP J Neurosci Res; 2021 Jan; 99(1):163-179. PubMed ID: 32633426 [TBL] [Abstract][Full Text] [Related]
26. D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population. Kalinderi K; Bostantjopoulou S; Katsarou Z; Dimikiotou M; Fidani L Neurosci Lett; 2015 Oct; 606():113-6. PubMed ID: 26300542 [TBL] [Abstract][Full Text] [Related]
27. Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases. Follett J; Bugarcic A; Collins BM; Teasdale RD Curr Protein Pept Sci; 2017; 18(7):687-701. PubMed ID: 26965691 [TBL] [Abstract][Full Text] [Related]
28. Parkinson's Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread. Ding Y; Li Y; Chhetri G; Peng X; Wu J; Wang Z; Zhao B; Zhao W; Li X Cells; 2021 Mar; 10(4):. PubMed ID: 33800686 [TBL] [Abstract][Full Text] [Related]
30. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340 [TBL] [Abstract][Full Text] [Related]
31. A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson's disease model. Wang W; Ma X; Zhou L; Liu J; Zhu X Hum Mol Genet; 2017 Feb; 26(4):781-789. PubMed ID: 28040727 [TBL] [Abstract][Full Text] [Related]
32. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease. Niu M; Zhao F; Bondelid K; Siedlak SL; Torres S; Fujioka H; Wang W; Liu J; Zhu X Aging Cell; 2021 May; 20(5):e13347. PubMed ID: 33745227 [TBL] [Abstract][Full Text] [Related]
33. The impact of VPS35 D620N mutation on alternative autophagy and its reversal by estrogen in Parkinson's disease. Shiraishi T; Bono K; Hiraki H; Manome Y; Oka H; Iguchi Y; Okano HJ Cell Mol Life Sci; 2024 Feb; 81(1):103. PubMed ID: 38409392 [TBL] [Abstract][Full Text] [Related]
34. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin. Malik BR; Godena VK; Whitworth AJ Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041 [TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Wang W; Wang X; Fujioka H; Hoppel C; Whone AL; Caldwell MA; Cullen PJ; Liu J; Zhu X Nat Med; 2016 Jan; 22(1):54-63. PubMed ID: 26618722 [TBL] [Abstract][Full Text] [Related]
36. Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up. Ishiguro M; Li Y; Yoshino H; Daida K; Ishiguro Y; Oyama G; Saiki S; Funayama M; Hattori N; Nishioka K Parkinsonism Relat Disord; 2021 Mar; 84():139-143. PubMed ID: 33611076 [TBL] [Abstract][Full Text] [Related]
37. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease. Williams ET; Chen X; Otero PA; Moore DJ Neurobiol Dis; 2022 Aug; 170():105768. PubMed ID: 35588987 [TBL] [Abstract][Full Text] [Related]
38. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress. McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383 [TBL] [Abstract][Full Text] [Related]
39. Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation. Follett J; Bugarcic A; Yang Z; Ariotti N; Norwood SJ; Collins BM; Parton RG; Teasdale RD J Biol Chem; 2016 Aug; 291(35):18283-98. PubMed ID: 27385586 [TBL] [Abstract][Full Text] [Related]
40. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. Tang FL; Liu W; Hu JX; Erion JR; Ye J; Mei L; Xiong WC Cell Rep; 2015 Sep; 12(10):1631-43. PubMed ID: 26321632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]